Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Murphy AD, Porter C, White A, Irving A, Adams R, Ray R, Casbard A, Mahmood RD, Karanth S, Zhou C, Pugh J, Wheeler C, Roberts V, Arnetoli G, Salih Z, Hasan J, Mitchell C, Morgan RD, Clamp AR, Jayson GC.
Murphy AD, et al. Among authors: hasan j.
Int J Gynecol Cancer. 2024 May 9:ijgc-2024-005455. doi: 10.1136/ijgc-2024-005455. Online ahead of print.
Int J Gynecol Cancer. 2024.
PMID: 38724236